Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers

Journal of Alternative and Complementary Medicine

Volumn 19, Issue 6, 2013, Pages 582-587

  Cicero, Arrigo F G ^a   Tartagni, Elisa ^a   Ferroni, Alienor ^a   De Sando, Valeria ^a   Grandi, Elisa ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BERBERINE; C REACTIVE PROTEIN; CREATINE KINASE; FIBRINOGEN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; HEART PALPITATION; HEART RATE; HUMAN; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VAGINAL DRYNESS; WAIST CIRCUMFERENCE;

BERBERINE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; ISOFLAVONES; LIPIDS; MATRIX METALLOPROTEINASES; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 84878780567     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2011.0624     Document Type: Article

References (32)

1. Lewis SJ. Risk of cardiovascular disease as a woman ages. J Reprod Med 2007; 52(2 Suppl): 147-151.
2. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 2007; 10(Suppl 1): 19-24.
3. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265-279.
4. Simon T. Why is cardiovascular health important in menopausal women? Climacteric 2006; 9(Suppl 1): 13-18.
5. Santen RJ, Allred DC, Ardoin SP, et al.; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95(7 Suppl 1): s1-s66.
6. Pilšáková L, Rieficanský I, Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res 2010; 59: 651-664.
7. Pase MP, Grima NA, Sarris J. The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr 2011; 93: 446-454.
8. Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007; 85: 1148-1156.
9. Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol 2009; 4: 553-563.
10. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal regulated kinase-dependent stabilization of hepatic low density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005; 25: 2170-2176.
11. Lee S, Lim HJ, Park JH, et al. Berberine induced LDLR upregulation involves JNK pathway. Biochem Biophys Res Commun 2007; 362: 853-857.
12. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006; 47: 1281-1288.
13. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999; 16: 716-730.
14. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
15. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem. 1978; 15: 121-130.
16. Wahlefeld AW. Triglyceride determination after enzymatic hydrolysis. In: Bermeyer HU (ed.). Methods of Enzymatic Analysis, 2nd English ed. New York: Academic Press, Inc., 1974. pp. 18-31.
17. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34: 1345-1353.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52.
21. Cicero AF, Derosa G, Manca M, et al. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007; 14(4-5): 193-198.
22. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med 2010; 28: 426-434.
23. Cicero AF, Dormi A, D'Addato S, et al. Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: the Brisighella Heart Study. J Womens Health 2010; 19: 133-137.
24. Howes LG, Howes JB, Knight DC. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 2006; 55: 203-211.
25. Mucci M, Carraro C, Mancino P, et al. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Minerva Ginecol 2006; 58: 323-334.
26. Chu MC, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008; 199: 526.e1-7.
27. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3123-3130.
28. Kumi-Diaka JK, Hassanhi M, Merchant K, Horman V. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J MedFood 2006; 9: 491-497.
29. Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMAinduced macrophages. Int J Cardiol 2011; 146: 153-158.
30. Lim CS, Shalhoub J, Gohel MS, Shepherd AC, Davies AH. Matrix metalloproteinases in vascular disease-a potential therapeutic target? Curr Vasc Pharmacol 2010; 8: 75-85.
31. Luo XH, Guo LJ, Shan PF, et al. Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos Int 2006; 17: 521-526.
32. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero AF. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009; 32: E124-132.